New debt for oral sleep-apnoea drug

Apnimed did not raise this money to keep the lights on. It raised it to build a launch machine. On April 6, the company said it had secured a senior secured credit facility worth up to $150 million from HealthCare Royalty Partners to prepare for the planned US launch of AD109, its experimental pill for obstructive sleep apnoea. The structure matters. Apnimed gets $50 million now, another $50 million only if the FDA approves the drug, and a third $50 million only if sales hit a preset milestone. That is not rescue financing. It is debt tied to the idea that a market may soon exist. (prnewswire.com) That market is unusually large and unusually unsatisfied. Obstructive sleep apnoea happens when the upper airway repeatedly collapses during sleep, cutting airflow and dropping oxygen levels. It is linked to high blood pressure, stroke, heart disease, obesity, and type 2 diabetes. CPAP remains the standard treatment, and it works. The problem is that many patients do not stick with it over time. The NIH says positive airway pressure is effective, but many people find long-term use difficult, which is exactly why drugmakers keep circling this disease. (nhlbi.nih.gov) AD109 is Apnimed’s attempt to turn that compliance problem into a pharmaceutical one. The pill combines aroxybutynin and atomoxetine. Apnimed says the pair is designed to increase upper-airway muscle tone during sleep, aiming at the mechanics of airway collapse rather than just the daytime sleepiness that sleep apnoea can leave behind. That is the key distinction. A lot of drugs around sleep apnoea treat consequences. AD109 is trying to treat the nightly obstruction itself. (apnimed.com) The company has enough clinical data to make that story plausible. In May 2025, Apnimed reported that its first pivotal Phase 3 trial, SynAIRgy, met its primary endpoint at 26 weeks, with treated participants showing a mean 55.6% reduction from baseline in the apnea-hypopnea index, or AHI. In July 2025, the second Phase 3 trial, LunAIRo, also hit its primary endpoint. In that study, patients on AD109 showed a mean 46.8% reduction in AHI at 26 weeks versus 6.8% with placebo, and the effect remained significant at week 51. Apnimed said no serious adverse events related to AD109 were reported in LunAIRo. (prnewswire.com) Those results explain why Apnimed is borrowing against a future product instead of waiting for approval and then scrambling. The company said it is on track to submit its New Drug Application later this quarter. If that filing lands soon, the debt gives Apnimed cash to hire, plan market access, and get ready for the slow grind that follows FDA review: pricing, reimbursement, physician education, and the harder task of persuading sleep clinics to think beyond masks and machines. (prnewswire.com) There is one catch. AD109 is not arriving in a world with no drug competition. In December 2024, the FDA approved Eli Lilly’s Zepbound as the first medication for moderate to severe obstructive sleep apnoea in adults with obesity. But Zepbound works through weight loss, is limited to a narrower patient group, and is given by injection. AD109 is chasing a different opening: a once-nightly pill for adults across a broad range of weight classes, aimed directly at airway collapse. If the FDA agrees with Apnimed’s data, the company will be trying to sell not just a drug, but a new treatment habit. (fda.gov)